** Shares of ophthalmic medical device company RxSight RXST.O fall 33% to $8.55 in extended trading
** RXST cut its 2025 sales forecast to the range of $120 million to $130 million, vs prior expectation of $160 million to $175 million
** Analysts, on average, expect 2025 sales to reach $167.6 million, according to data compiled by LSEG
** Company also expects preliminary Q2 sales to be about $33.6 million, below analysts' estimates of $39.8 million
** J.P. Morgan analysts say the company's update reflects a "continued worsening of trends first seen last quarter rather than a hopeful improvement, a concerning trend set to continue into 2H25 with no clear resolution in sight"
** Stock down 62.8%, YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.